PBK抗体

+ +

•  

   

     Black line: Control Antigen (100 ng); Purple line: Antigen(10ng); Blue line: Antigen (50 ng); Red line: Antigen (100 ng);    

  
  

•  

   

     Western blot analysis using PBK mouse mAb against A431 (1) cell lysate.    

  
  

•  

   

     Immunofluorescence analysis of Hela cells using PBK mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor-555 phalloidin.    

  
  

•  

   

     Flow cytometric analysis of Hela cells using PBK mouse mAb (green) and negative control (red).    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human ovarian cancer tissues using PBK mouse mAb with DAB staining.    

  
  

•  

   

     Figure5: Immunohistochemical analysis of paraffin-embedded human colon cancer tissues using PBK mouse mAb with DAB staining.    

  
  

PBK (PDZ-binding kinase), also known as TOPK (T-LAK cell-originated protein kinase), is a serine/threonine kinase belonging to the mitogen-activated protein kinase (MAPK) family. Discovered in 2000. PBK plays critical roles in cell cycle regulation, DNA damage response, and tumorigenesis. It interacts with key signaling pathways, including the p53 and PLK1 networks, influencing processes like cytokinesis, apoptosis, and cell proliferation. Structurally, PBK contains an N-terminal catalytic domain and a C-terminal PDZ-binding motif that mediates protein-protein interactions.

PBK is predominantly overexpressed in various cancers (e.g., breast, lung, glioblastoma) and correlates with poor prognosis, making it a potential therapeutic target. Its aberrant activation promotes tumor growth, metastasis, and therapy resistance by enhancing DNA repair and survival mechanisms. PBK antibodies are essential tools for detecting PBK expression in research and diagnostics, particularly in immunohistochemistry (IHC), Western blotting, and flow cytometry. They help elucidate PBK's functional roles, validate knockout models, and assess its clinical relevance in cancer progression. Recent studies also explore PBK inhibitors in combination therapies to sensitize cancer cells to chemo- or radiotherapy. However, PBK's dual roles in normal physiology (e.g., embryonic development, immune regulation) necessitate careful evaluation of therapeutic strategies targeting this kinase.